NURC
NOTICE OF UPDATED REGISTRATION CONFIRMATION EMAILED
03/03/2026
Back to search
Official data from USPTO
3DµS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
43
Latest update
04/03/2026
Trademark type
Combined
Nice classes
5, 7, 42
Filing date
02/22/2024
Registration date
07/15/2025
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
07/15/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
03
Owner location
CN
Examiner
LAM, HAI-LY HUYNH
Current location
Historical data usage
Mark description
The mark consists of the stylized wording "3DµS".
Holders and representatives
Holders
Triastek, Inc.
Representatives
Alex Patel Patel IP, P.C.
Technical classification
Nice Classes
Class 5Class 7Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Veterinary preparationsveterinary vaccinesgreases for veterinary purposesantibiotics for veterinary purposesbacterial preparations for veterinary purposesveterinary diagnostic reagentsantibodies for veterinary purposesanti-infective products for veterinary use; dietetic foods adapted for medical purposes; sugar for medical purposes; dental resin for temporary bridgescrowns and veneers; pharmaceutical preparations for the treatment of bone diseases; biological tissue cultures for medical purposes; fever blister treatment preparations; dysmenorrhea treatment preparations; pharmaceutical preparations for the central nervous system; oral analgesics; anticoagulants; tumor suppressing agents; pharmaceutical preparationsa drug delivery system comprising polymer-based oral tablets for the continuous release of a wide variety of therapeutic agents; pharmaceutical preparations for the treatment of musculoskeletal disorders; pharmaceutical preparations for inducing erections; stimulants for the central nervous system; pharmaceutical preparations for treating allergies; anti-diabetic pharmaceuticals; calcium channel blockers; medicinal preparations for the mouth to be applied in the form of tablets; pharmaceutical preparations for the prevention and treatment of cancer; niacinamide preparations for the treatment of acne; pharmaceutical preparations for suppressing tumors; pharmaceutical preparations for treating hypoglycemia; antihypertensives; chemotherapeutics; antivirals; anti-infectives; chemico-pharmaceutical preparations for the treatment of canceroncological diseasescardiovascular and cerebrovascular diseasesrespiratory diseasesgenitourinary diseasesneurological diseasesimmune system related diseasesgastrointestinal diseasesmusculoskeletal diseases and endocrine metabolism-related diseases; living cells for medical use; parathyroid hormone preparations; contraceptive preparations; medicines for the treatment of cardiovascular and cerebrovascular diseases; hypnotic sedatives; pharmaceutical products for treating respiratory diseases
Class 7
Machines for the pharmaceutical processing industryprint heads for 3D printers for drugs and vaccine preparationsprint heads for pharmaceutical drug and vaccine printing machinesindustrial robots for conveying of drugs and vaccine preparationspackaging machines for drugs and vaccine preparations; machines for the pharmaceutical processing industryfor producing drug and vaccine capsules and tablets and mixing machines for drugs and vaccines; 3D printers * for pharmaceutical processing industry; * 3D bioprinters * for pharmaceutical processing industry *
Class 42
Scientific research for medical purposes in the field of cancerous diseases; pharmaceutical research services; testing of pharmaceuticals; research and development services in the field of medicines; development of pharmaceutical preparations and medicines; pharmaceutical research and development; pharmaceutical drug development services; pharmaceutical product evaluation; conducting early evaluations in the field of new pharmaceuticals; technical research in the field of pharmaceutical studies; quality testing of pharmaceutical product; advisory services relating to material testing
Publications
History of USPTO decisions and trademark events.
43 publications found
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/26/2026
FICS
FINAL DISPOSITION NOTICE SENT TO IB
02/11/2026
LIME
LIMITATION FROM THE IB EXAMINED AND ENTERED
02/11/2026
FIMP
FINAL DISPOSITION PROCESSED
02/11/2026
COC.
CORRECTION UNDER SECTION 7 - PROCESSED
02/11/2026
APRE
CASE ASSIGNED TO POST REGISTRATION PARALEGAL
02/11/2026
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
01/22/2026
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
01/07/2026
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
01/07/2026
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
10/15/2025
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
08/22/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
07/15/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
07/15/2025
ETOP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
06/25/2025
ETOF
EXTENSION OF TIME TO OPPOSE RECEIVED
05/15/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
04/15/2025
PUBO
PUBLISHED FOR OPPOSITION
04/15/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
04/09/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
03/21/2025
XAEC
EXAMINER'S AMENDMENT ENTERED
02/25/2025
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
02/25/2025
GNEA
EXAMINERS AMENDMENT E-MAILED
02/25/2025
CNEA
EXAMINERS AMENDMENT -WRITTEN
02/25/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
02/24/2025
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
02/24/2025
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
02/24/2025
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
01/17/2025
GNFR
FINAL REFUSAL E-MAILED
01/17/2025
CNFR
FINAL REFUSAL WRITTEN
01/17/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
12/20/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
12/20/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
12/20/2024
RFNT
REFUSAL PROCESSED BY IB
10/08/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/17/2024
RFRR
REFUSAL PROCESSED BY MPU
09/16/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/14/2024
CNRT
NON-FINAL ACTION WRITTEN
09/13/2024
DOCK
ASSIGNED TO EXAMINER
09/11/2024
MAFR
APPLICATION FILING RECEIPT MAILED
08/19/2024
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/19/2024
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
08/15/2024
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
08/08/2024
Continuous trademark protection
Get notified about every new filing that threatens 3DµS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.